['hiv-1 infection']
['abc/dtg/3tc', 'b/f/taf', 'abc/dtg/3tc placebo', 'b/f/taf placebo']

        Key Inclusion Criteria:

          -  Antiretroviral treatment naïve (≤ 10 days of prior therapy with any antiretroviral
             agent following a diagnosis of HIV-1 infection) except the use for pre-exposure
             prophylaxis (PrEP) or post-exposure prophylaxis (PEP), up to one month prior to
             screening

          -  Plasma HIV-1 RNA levels ≥ 500 copies/mL at screening

          -  Adequate renal function: Estimated glomerular filtration rate ≥ 50 mL/min (≥ 0.83
             mL/sec) according to the Cockcroft-Gault formula

          -  Negative screening test for human leukocyte antigen (HLA) -B x 5701 allele provided by
             Gilead Sciences

        Key Exclusion Criteria:

          -  An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior
             to screening (refer to study protocol)

          -  Decompensated cirrhosis (e.g, ascites, encephalopathy, or variceal bleeding)

          -  Current alcohol or substance use judged by the Investigator to potentially interfere
             with subject study compliance

          -  Females who are pregnant (as confirmed by positive serum pregnancy test)

          -  Females who are breastfeeding

          -  Chronic Hepatitis B Virus (HBV) infection

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      